Invesco DB Commodity Index Tracking Fund vs Royalty Pharma plc Class A Ordinary Shares — how do they compare? Invesco DB Commodity Index Tracking Fund trades at $33.07 (market cap $1.92B), while Royalty Pharma plc Class A Ordinary Shares trades at $56.96 (market cap $25.27B). The key difference: Royalty Pharma plc Class A Ordinary Shares is far larger — about 13.2× Invesco DB Commodity Index Tracking Fund's market cap, and Royalty Pharma plc Class A Ordinary Shares pays a 1.66% dividend while Invesco DB Commodity Index Tracking Fund pays none. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Commodity Index Tracking Fund for 60 Days and Royalty Pharma plc Class A Ordinary Shares for 1 Days on average.
| DBC | RPRX | |
|---|---|---|
Market Cap | $1.92B | $25.27B |
Volume | 1,375,556 | 3,671,183 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $33.68 | $63.96 |
52-Week Low | $22.07 | $35.44 |
Typical Hold Time | 60 Days | 1 Days |
Enterprise Value | — | $32.50B |
Dividend Yield | — | 1.66% |
Signals from Pluang's Aura AI — not financial advice
DBC trades at $32.51, down 0.55% today, with a bullish technical signal from moving averages. The company reported $82.59M revenue and $22.38M net income for 2024, showing improved profitability with a 27.1% margin. Cash flow from operations was strong at $431.54M, though total assets declined from $2.7B in 2021 to $1.29B currently. Technical indicators show support at $32 and resistance at $33.
DBC demonstrates solid operational cash generation despite asset base contraction. The zero-debt balance sheet provides financial stability, but declining revenue from 2023's $108M raises growth concerns. Current valuation metrics remain undisclosed, requiring deeper analysis. The stock's technical strength suggests near-term upside potential if fundamental performance stabilizes.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
DBC is a diversified commodity ETF that tracks the DBIQ Optimum Yield Diversified Commodity Index. It invests in futures contracts for 14 heavily traded commodities, including crude oil, gold, and corn, while optimizing for yield and roll costs.
Read more on DBC →Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →